Upon completion of this educational activity, participants should be able to:
- describe new findings in the differential diagnosis and treatment of various diseases;
- describe the advantages, disadvantages, and controversies surrounding the latest advances in the diagnosis and treatment of disease;
- identify cost-effective treatment regimens;
- explain the advantages and disadvantages of new disease screening procedures.
Relias LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Relias LLC designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
This Enduring Material activity, Internal Medicine Alert, has been reviewed and is acceptable for credit by the American Academy of Family Physicians. Term of approval begins 1/15/2019. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Approved for 2 AAFP Prescribed credits.
The American Osteopathic Association has approved this continuing education activity for up to 2 AOA Category 2-B credits.
Internal Medicine Alert’s Physician Editor Stephen Brunton, MD, is a retained consultant for Abbott, Acadia, Allergan, AstraZeneca, Avadel, Boehringer Ingelheim, GlaxoSmithKline, Janssen, Mylan, and Salix; he serves on the speakers bureau of AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, and Novo Nordisk. Peer Reviewer Gerald Roberts, MD; Editor Jonathan Springston; Editor Jason Schneider; Editorial Group Manager Leslie Coplin; and Accreditations Manager Amy M. Johnson, MSN, RN, CPN, report no financial relationships relevant to this field of study.